The Lancet Oncology
Published: 07 December 2017
DOI: http://dx.doi.org/10.1016/S1470-2045(17)30905-1
Roberto Salgado, Sherene Loi
Background: The immune microenvironment is now recognised as crucial in the treatment of cancer. The tumour immune infiltrate has been noted to be associated with better outcomes in HER2-positive breast cancer and triple-negative breast cancer (TNBC), in both the early-stage and the advanced disease setting.
Comentarios
Para dejar un comentario antes debes iniciar sesión:
¿No tienes una cuenta?
Regístrate a través de éste enlace.